Health
GSK’s 5-in-1 Meningococcal Vaccine PENMENVY Receives Positive Recommendation from US Advisory Committee on Immunization Practices
PHILADELPHIA, April 16, 2025--GSK’s 5-in-1 meningococcal vaccine PENMENVY receives positive recommendation from US Advisory Committee on Immunization Practices
About this update from Gsk Plc
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":480,"height":271,"url":"https://media.zenfs.com/en/business-wire.com/35ce930912a6f3b4ef7e52a7d4f0e3ea"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/FXIddEA_061C4ONdDwQ_BA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTU0MjtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/35ce930912a6f3b4ef7e52a7d4f0e3ea","width":480,"height":271}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Vaccine recommended to help protect persons over 10 years old in the United States (US) against disease-causing serogroups of Neisseria meningitidis (A, B, C, W, and Y)","length":168,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Broad serogroup coverage in one vaccine reduces injections to help improve vaccination rates and help protect more US adolescents and young adults","length":146,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Vaccine doses will be ready for use in the US from Summer 2025","length":62,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":376,"olType":false},{"type":"text","content":"PHILADELPHIA, April 16, 2025--(BUSINESS WIRE)--GSK plc (LSE/NYSE: GSK) today announced that the US Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP) has voted to recommend use of PENMENVY (Meningococcal Groups A, B, C, W, and Y Vaccine) as part of the adolescent meningococcal vaccination schedule. Recommendations made by the ACIP are reviewed and, if adopted, are published as official CDC recommendations.","length":461,"tagName":"p"},{"type":"text","content":"ACIP voted to recommend that persons over 10 years old receive a single dose of PENMENVY as an alternative to separate administration of meningococcal serogroups A, C, W, and Y (MenACWY) and meningococcal serogroup B (MenB) vaccinations when both vaccines would be given on the same clinic visit, typically at age 16. This recommendation, if adopted, will allow for vaccination against serogroups A, B, C, W, and Y in fewer doses, could simplify meningococcal vaccination delivery and could improve immunization rates, helping protect more US adolescents against these five disease-causing serogroups for which the US CDC has previously issued re...